Can you provide the average price target for ANGION BIOMEDICA CORP stock?
6 analysts have analysed ANGN and the average price target is 1.53 USD. This implies a price increase of 53% is expected in the next year compared to the current price of 1.
ANGION BIOMEDICA CORP (ANGN) Forecast, Price Target & Analyst Ratings
NASDAQ:ANGN • US03476J1079
Current stock price
1 USD
+0.02 (+2.04%)
At close:
0.9437 USD
-0.06 (-5.63%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ANGION BIOMEDICA CORP (ANGN).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
$1.53
Upside
+ 53.00%
From current price of $1.00 to mean target of $1.53, Based on 6 analyst forecasts
Low
$1.52
Median
$1.53
High
$1.58
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
6 Wall Street analysts provided a forecast for the next 12 months for ANGN. The average price target is 1.53 USD. This implies a price increase of 53% is expected in the next year compared to the current price of 1.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
ANGN was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about ANGN.
In the previous month the buy percentage consensus was at a similar level.
ANGN was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-07-18 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-06-30 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-06-30 | Stifel | Downgrade | Buy -> Hold |
| 2022-05-23 | HC Wainwright & Co. | Maintains | Buy |
| 2022-04-18 | HC Wainwright & Co. | Maintains | Buy |
| 2021-12-10 | Oppenheimer | Maintains | Outperform |
| 2021-11-09 | HC Wainwright & Co. | Maintains | Buy |
| 2021-10-27 | Stifel | Maintains | Buy |
| 2021-03-02 | Oppenheimer | Initiate | Outperform |
| 2021-03-02 | Stifel | Initiate | Buy |
| 2021-03-02 | Cowen & Co. | Initiate | Outperform |
| 2021-03-01 | HC Wainwright & Co. | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Aug 14, 2023
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2023 - 2025
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.88M 93.29% | 28.312M 883.06% | 2.301M -91.87% | -100.00% | |||
| EBITDA YoY % growth | -55.17M -43.15% | -39.216M 28.92% | -30.258M 22.84% | -41.83M -38.25% | -46.657M -11.54% | N/A | |
| EBIT YoY % growth | -55.27M -43.22% | -39.307M 28.88% | -30.436M 22.57% | -25.5M 16.22% | -20.4M 20.00% | -20.4M | |
| Operating Margin | -1,919.10% | -138.84% | -1,322.73% | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -2.09 64.67% | -1.29 38.28% | -0.85 34.37% | -0.54 36.14% | -0.45 16.98% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
18.22%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
ANGION BIOMEDICA CORP / ANGN Forecast FAQ
Can you provide the upcoming earnings date for ANGION BIOMEDICA CORP?
ANGION BIOMEDICA CORP (ANGN) will report earnings on 2023-08-14.
What is the consensus rating for ANGN stock?
The consensus rating for ANGION BIOMEDICA CORP (ANGN) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.